Information about pharmaceutical companies that develop and produce Enasidenib

Enasidenib is a targeted drug developed by Celgene Corporation. It is mainly used to treat acute myeloid leukemia (AML) . Celgene Pharmaceuticals was founded in 1986 and is headquartered in New Jersey, USA. It is one of the world's leading biopharmaceutical companies. In 2019, Celgene was acquired by global pharmaceutical giant Bristol-Myers Squibb (BMS) and became its subsidiary.

Celgene Pharmaceuticals has been committed to the research and development of innovative drugs, especially in the fields of cancer, immunology and inflammation. Ensidipine is one of Celgene's innovations in the field of oncology. It is specially used to treat patients with acute myeloid leukemia who carry IDH2 gene mutations. IDH2 gene mutation is a common molecular marker in AML patients. Ensidipine restores normal cell differentiation and inhibits the proliferation of leukemia cells by targeting the IDH2 gene mutation.

During the drug research and development process, Celgene Pharmaceuticals works closely with multiple scientific research institutions and hospitals around the world to provide patients with more effective treatment options. The successful development of ensidipine marks an important breakthrough for Celgene Pharmaceuticals in the field of anti-tumor drugs and is also one of its innovations in the field of hematological tumor treatment.

The launch and promotion of ensidipine has enabled Celgene Pharmaceuticals to further consolidate its position in the field of cancer treatment. As a targeted drug, ensidipine can not only improve the prognosis of AML patients, but also provide new treatment options for patients who are not suitable for traditional chemotherapy. After Bristol-Myers Squibb acquired Celgene Pharmaceuticals, ensidipine's global market layout and clinical promotion have been further strengthened, helping more patients benefit from this innovative treatment option. Innovative progress in the field of targeted therapy has also allowed the company to occupy an important position in the global biopharmaceutical industry.

Reference materials:https://www.idhifa.com/